Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 13.53M | 27.51M | 27.43M | 11.04M | 6.58M | 4.80M |
Gross Profit | 4.58M | 16.95M | 15.60M | 4.30M | 3.63M | -4.08M |
EBITDA | -27.51M | -40.49M | -43.62M | -36.00M | -15.49M | -6.12M |
Net Income | -45.55M | -47.72M | -48.47M | -38.96M | -18.01M | -8.30M |
Balance Sheet | ||||||
Total Assets | 24.74M | 70.41M | 81.36M | 116.26M | 26.86M | 38.76M |
Cash, Cash Equivalents and Short-Term Investments | 4.51M | 19.16M | 43.75M | 82.81M | 13.46M | 29.14M |
Total Debt | 16.29M | 34.38M | 21.43M | 17.32M | 8.33M | 4.77M |
Total Liabilities | 20.86M | 40.87M | 34.80M | 25.47M | 52.32M | 46.26M |
Stockholders Equity | 3.87M | 29.54M | -113.74M | 90.78M | -25.46M | -7.50M |
Cash Flow | ||||||
Free Cash Flow | -23.74M | -36.65M | -43.18M | -38.55M | -15.59M | -6.47M |
Operating Cash Flow | -22.85M | -34.67M | -38.72M | -36.70M | -15.38M | -6.39M |
Investing Cash Flow | 24.32M | -5.74M | -18.01M | -15.04M | -204.00K | -79.00K |
Financing Cash Flow | -15.22M | 11.56M | 4.51M | 121.08M | -96.00K | 35.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.26 | -41.41% | 2.22% | 22.87% | -2.01% | |
51 Neutral | $8.39M | 0.42 | -499.57% | ― | -73.36% | ― | |
49 Neutral | $32.50M | ― | -262.03% | ― | 2.65% | 70.21% | |
43 Neutral | $3.35M | ― | -160.96% | ― | -58.49% | 84.67% | |
38 Underperform | $4.19M | ― | -1294.96% | ― | 14.74% | -2.42% | |
36 Underperform | $940.72K | ― | -175.00% | ― | -54.89% | -19.78% | |
― | $3.86M | ― | -88.80% | ― | ― | ― |
Telesis Bio Inc. announces the departure of Chief Legal Officer Robert H. Cutler on October 31, 2024, with a comprehensive severance package including $307,500 and nine months of COBRA premiums, contingent on the company’s financial milestones. Cutler will aid in his role transition through a consulting agreement.